A rapidly growing biotechnology company that is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology. Our partner is committed to developing a differentiated class of therapeutics for oncology indications and more.

This critical hire utilized their extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases to drive our partner’s success. They were responsible for designing and driving clinical development plans for our client’s pipeline candidates, all of which represented first-in-class or best-in-class therapies.